HEPATITIS B TREATMENT VACCINE ON THE BASIS OF INACTIVATED, FULLY RECOMBINANT HANSENULA CELLS EXPRESSING HBSAG

Title:

HEPATITIS B TREATMENT VACCINE ON THE BASIS OF INACTIVATED, FULLY RECOMBINANT HANSENULA CELLS EXPRESSING HBSAG

Document Type and Number:

WIPO Patent Application WO/2017/162091

Kind Code:

A1

Abstract:

A hepatitis B treatment vaccine on the basis of inactivated, fully recombinant Hansenula cells expressing HBsAg. The vaccine is the HBsAg expressed in recombinant Hansenula cells. 108 cells contain 6-10μg HBsAg as an antigen; the vaccine contains a total of 16-21 HBsAg-specific CTL epitopes; the vaccine uses optimized inactivated, fully recombinant Hansenula cells as an adjuvant.

Inventors:

WANG HEMU (CN)
WANG CHANGHUA (CN)
YANG JUN (CN)

Application Number:

PCT/CN2017/076933

Publication Date:

September 28, 2017

Filing Date:

March 16, 2017

Export Citation:

Click for automatic bibliography generation Help

Assignee:

WANG HEMU (CN)

International Classes:

A61K39/29; A61K39/39; A61P31/20; C12N1/19; C12R1/78

Foreign References:

CN102038948A	2011-05-04
CN1651570A	2005-08-10

Other References: